News

The data shows that significant majority of patients on study have experienced tumor shrinkage with prolonged duration of stable disease, highlight the potential utility of drug and its

The study will evaluate the safety and initial efficacy of Adhexil in preventing and/or reducing post-operative adhesions in patients undergoing gynecological surgery of the ovaries. The clinical trial

The shares of Optimer’s common stock to be sold in the private placement have not been registered under the Securities Act of 1933, as amended or state securities

The single ascending dose study is being conducted in the US under an exploratory investigational new drug application and will evaluate the safety and pharmacokinetics of three doses

In the Phase I study, R1507 was administered by intravenous infusion. Nine of 34 adult patients with advanced solid tumors experienced disease stabilization. Four of the seven heavily

BioSante’s board of directors has approved the decision to switch the listing of BioSante’s common stock from the American Stock Exchange to the Nasdaq stock global market. BioSante’s

As a result of approving this indication, Sigmart injection is considered to offer a new therapeutic option to patients who need intravenous administration of vasodilators. Sigmart injection is

The primary endpoint of the study is overall survival and time to objective disease progression is a secondary endpoint. The company currently expects an interim analysis for overall

The trial demonstrated objective evidence of efficacy in 10 of the 13 evaluable patients with advanced treatment-refractory tumors in the liver (primary and metastatic). Responses were particularly encouraging